Abstract
Multiple proven and potential risk factors for the development of rheumatoid arthritis (RA) have been identified, and represent interactions between genes and the environment. Proven risk factors include genetic influences on the function of the innate and adaptive immune systems, smoking, anti-citrullinated protein antibodies (ACPAs), and rheumatoid factors (RF). Potential risk factors include epigenetic control of gene expression, the microbiome and other environmental factors, Toll-like receptors, cytokines, and Fc receptors. Preclinical abnormalities such as circulating RF and ACPAs may occur more than 10 years prior to the onset of clinical disease. However, the precise mechanisms whereby these risk factors lead to clinical disease remain unclear. It is possible that, combined with activation of the innate immune system, a subset of ACPAs initiates the disease in the cartilage or synovium after binding to endogenous citrullinated proteins. Subsequent engagement of Fc receptors and complement activation would lead to secondary inflammation in the synovium with induction of a perpetuating cycle of chronic synovitis.
Key Points
-
Rheumatoid arthritis (RA) exhibits multiple predisposing factors that precede its development
-
Genetic risk factors are prominent, involving genes of the MHC as well as many non-MHC genes associated with immune responses and inflammation
-
The presence of elevated serum levels of autoantibodies such as rheumatoid factors and antibodies to citrullinated proteins may precede the clinical onset of RA by over 10 years and could, in some cases, represent a normal adaptive response to neoantigens
-
The most important environmental risk factor for RA defined to date is smoking
-
The precise mechanism of initiation of the clinical disease is unknown but may involve antibodies directed against specific citrullinated proteins and repeated activation of innate immunity
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
McInnes, I. B. & Schett, G. The pathogenesis of rheumatoid arthritis. N. Engl. J. Med. 365, 2205–2219 (2011).
Klareskog, L., Ronnelid, J., Lundberg, K., Padyukov, L. & Alfredsson, L. Immunity to citrullinated proteins in rheumatoid arthritis. Annu. Rev. Immunol. 26, 651–675 (2008).
Deane, K. D., Norris, J. M. & Holers, V. M. Preclinical rheumatoid arthritis: identification, evaluation, and future directions for investigation. Rheum. Dis. Clin. North Am. 36, 213–241 (2010).
Raychaudhuri, S. Recent advances in the genetics of rheumatoid arthritis. Curr. Opin. Rheumatol. 22, 109–118 (2010).
Deane, K. D. Learning about the natural history of rheumatoid arthritis development through prospective study of subjects at high risk of rheumatoid arthritis-related autoimmunity. Arthritis Rheum. 64, 1708–1712 (2012).
MacGregor, A. J. et al. Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins. Arthritis Rheum. 43, 30–37 (2000).
van der Woude, D. et al. Quantitative heritability of anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis. Arthritis Rheum. 60, 916–923 (2009).
Deighton, C. M., Walker, D. J., Griffiths, I. D. & Roberts, D. F. The contribution of HLA to rheumatoid arthritis. Clin. Genet. 36, 178–182 (1989).
Stastny, P. Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N. Engl. J. Med. 298, 869–871 (1978).
van der Woude, D. et al. Protection against anti-citrullinated protein antibody-positive rheumatoid arthritis is predominantly associated with HLA-DRB1*1301: a meta-analysis of HLA-DRB1 associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in four European populations. Arthritis Rheum. 62, 1236–1245 (2010).
Gregersen, P. K., Silver, J. & Winchester, R. J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 30, 1205–1213 (1987).
Huizinga, T. W. et al. Refining the complex rheumatoid arthritis phenotype based on specificity of the HLA-DRB1 shared epitope for antibodies to citrullinated proteins. Arthritis Rheum. 52, 3433–3438 (2005).
van der Helm-van Mil, A. H. et al. The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum. 54, 1117–1121 (2006).
Hill, J. A. et al. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J. Immunol. 171, 538–541 (2003).
De Almeida, D. E. et al. Immune dysregulation by the rheumatoid arthritis shared epitope. J. Immunol. 185, 1927–1934 (2010).
Lee, H. S. et al. Several regions in the major histocompatibility complex confer risk for anti-CCP-antibody positive rheumatoid arthritis, independent of the DRB1 locus. Mol. Med. 14, 293–300 (2008).
Ding, B. et al. Different patterns of associations with anti-citrullinated protein antibody-positive and anti-citrullinated protein antibody-negative rheumatoid arthritis in the extended major histocompatibility complex region. Arthritis Rheum. 60, 30–38 (2009).
Vignal, C. et al. Genetic association of the major histocompatibility complex with rheumatoid arthritis implicates two non-DRB1 loci. Arthritis Rheum. 60, 53–62 (2009).
Raychaudhuri, S. et al. Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis. Nat. Genet. 44, 291–296 (2012).
Karlson, E. W. et al. Cumulative association of 22 genetic variants with seropositive rheumatoid arthritis risk. Ann. Rheum. Dis. 69, 1077–1085 (2010).
Begovich, A. B. et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am. J. Hum. Genet. 75, 330–337 (2004).
Zikherman, J. & Weiss, A. Unraveling the functional implications of GWAS: how T cell protein tyrosine phosphatase drives autoimmune disease. J. Clin. Invest. 121, 4618–4621 (2011).
Vang, T. et al. Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. Nat. Genet. 37, 1317–1319 (2005).
Wiede, F. et al. T cell protein tyrosine phosphatase attenuates T cell signaling to maintain tolerance in mice. J. Clin. Invest. 121, 4758–4774 (2011).
Stahl, E. A. et al. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat. Genet. 44, 483–489 (2012).
Okada, Y. et al. Meta-analysis identifies nine new loci associated with rheumatoid arthritis in the Japanese population. Nat. Genet. 44, 511–516 (2012).
Verpoort, K. N. et al. Association of HLA-DR3 with anti-cyclic citrullinated peptide antibody-negative rheumatoid arthritis. Arthritis Rheum. 52, 3058–3062 (2005).
Sigurdsson, S. et al. Association of a haplotype in the promoter region of the interferon regulatory factor 5 gene with rheumatoid arthritis. Arthritis Rheum. 56, 2202–2210 (2007).
Padyukov, L. et al. A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann. Rheum. Dis. 70, 259–265 (2011).
Richardson, B. Primer: epigenetics of autoimmunity. Nat. Clin. Pract. Rheumatol. 3, 521–527 (2007).
Robertson, K. D. DNA methylation and human disease. Nat. Rev. Genet. 6, 597–610 (2005).
Meinecke, I. et al. Modification of nuclear PML protein by SUMO-1 regulates Fas-induced apoptosis in rheumatoid arthritis synovial fibroblasts. Proc. Natl Acad. Sci. USA 104, 5073–5078 (2007).
Kim, J. K., Samaranayake, M. & Pradhan, S. Epigenetic mechanisms in mammals. Cell. Mol. Life Sci. 66, 596–612 (2009).
Trenkmann, M., Brock, M., Ospelt, C. & Gay, S. Epigenetics in rheumatoid arthritis. Clin. Rev. Allergy Immunol. 39, 10–19 (2010).
Ospelt, C., Reedquist, K. A., Gay, S. & Tak, P. P. Inflammatory memories: is epigenetics the missing link to persistent stromal cell activation in rheumatoid arthritis? Autoimmun. Rev. 10, 519–524 (2011).
Firestein, G. S. Invasive fibroblast-like synoviocytes in rheumatoid arthritis. Passive responders or transformed aggressors? Arthritis Rheum. 39, 1781–1790 (1996).
Horiuchi, M. et al. Expression and function of histone deacetylases in rheumatoid arthritis synovial fibroblasts. J. Rheumatol. 36, 1580–1589 (2009).
Rosenfeld, C. S. Animal models to study environmental epigenetics. Biol. Reprod. 82, 473–488 (2010).
Hollingsworth, J. W. et al. In utero supplementation with methyl donors enhances allergic airway disease in mice. J. Clin. Invest. 118, 3462–3469 (2008).
Stanczyk, J. et al. Altered expression of microRNA-203 in rheumatoid arthritis synovial fibroblasts and its role in fibroblast activation. Arthritis Rheum. 63, 373–381 (2011).
Stanczyk, J. et al. Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis. Arthritis Rheum. 58, 1001–1009 (2008).
Filipowicz, W., Bhattacharyya, S. N. & Sonenberg, N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat. Rev. Genet. 9, 102–114 (2008).
Duroux-Richard, I., Jorgensen, C. & Apparailly, F. What do microRNAs mean for rheumatoid arthritis? Arthritis Rheum. 64, 11–20 (2012).
Ebert, M. S. & Sharp, P. A. Roles for microRNAs in conferring robustness to biological processes. Cell 149, 515–524 (2012).
Mendell, J. T. & Olson, E. N. MicroRNAs in stress signaling and human disease. Cell 148, 1172–1187 (2012).
Renz, H., Brandtzaeg, P. & Hornef, M. The impact of perinatal immune development on mucosal homeostasis and chronic inflammation. Nat. Rev. Immunol. 12, 9–23 (2012).
Macpherson, A. J. & Harris, N. L. Interactions between commensal intestinal bacteria and the immune system. Nat. Rev. Immunol. 4, 478–485 (2004).
Round, J. L. & Mazmanian, S. K. The gut microbiota shapes intestinal immune responses during health and disease. Nat. Rev. Immunol. 9, 313–323 (2009).
Chervonsky, A. V. Influence of microbial environment on autoimmunity. Nat. Immunol. 11, 28–35 (2010).
Toivanen, P. Normal intestinal microbiota in the aetiopathogenesis of rheumatoid arthritis. Ann. Rheum. Dis. 62, 807–811 (2003).
Scher, J. U. & Abramson, S. B. The microbiome and rheumatoid arthritis. Nat. Rev. Rheumatol. 7, 569–578 (2011).
Horai, R. et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J. Exp. Med. 191, 313–320 (2000).
Abdollahi-Roodsaz, S. et al. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis. J. Clin. Invest. 118, 205–216 (2008).
Wu, H. J. et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32, 815–827 (2010).
Tilg, H. Diet and intestinal immunity. N. Engl. J. Med. 366, 181–183 (2012).
Faith, J. J., McNulty, N. P., Rey, F. E. & Gordon, J. I. Predicting a human gut microbiota's response to diet in gnotobiotic mice. Science 333, 101–104 (2011).
Dethlefsen, L. & Relman, D. A. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc. Natl Acad. Sci. USA 108 (Suppl. 1), 4554–4561 (2011).
Mills, K. H. TLR-dependent T cell activation in autoimmunity. Nat. Rev. Immunol. 11, 807–822 (2011).
Santegoets, K. C., van Bon, L., van den Berg, W. B., Wenink, M. H. & Radstake, T. R. Toll-like receptors in rheumatic diseases: are we paying a high price for our defense against bugs? FEBS Lett. 585, 3660–3666 (2011).
Marshak-Rothstein, A. Toll-like receptors in systemic autoimmune disease. Nat. Rev. Immunol. 6, 823–835 (2006).
Goh, F. G. & Midwood, K. S. Intrinsic danger: activation of Toll-like receptors in rheumatoid arthritis. Rheumatology 51, 7–23 (2012).
Tamaki, Y. et al. Expression of Toll-like receptors and their signaling pathways in rheumatoid synovitis. J. Rheumatol. 38, 810–820 (2011).
Choe, J. Y., Crain, B., Wu, S. R. & Corr, M. Interleukin 1 receptor dependence of serum transferred arthritis can be circumvented by toll-like receptor 4 signaling. J. Exp. Med. 197, 537–542 (2003).
Carty, S. M., Snowden, N. & Silman, A. J. Should infection still be considered as the most likely triggering factor for rheumatoid arthritis? J. Rheumatol. 30, 425–429 (2003).
Vandenbroucke, J. P. et al. Frequency of infections among rheumatoid arthritis patients, before and after disease onset. Arthritis Rheum. 30, 810–813 (1987).
Darrah, E., Rosen, A., Giles, J. T. & Andrade, F. Peptidylarginine deiminase 2, 3 and 4 have distinct specificities against cellular substrates: novel insights into autoantigen selection in rheumatoid arthritis. Ann. Rheum. Dis. 71, 92–98 (2012).
Suzuki, A. et al. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34, 395–402 (2003).
Kochi, Y. et al. PADI4 polymorphism predisposes male smokers to rheumatoid arthritis. Ann. Rheum. Dis. 70, 512–515 (2011).
Harris, M. L. et al. Association of autoimmunity to peptidyl arginine deiminase type 4 with genotype and disease severity in rheumatoid arthritis. Arthritis Rheum. 58, 1958–1967 (2008).
Kolfenbach, J. R. et al. Autoimmunity to peptidyl arginine deiminase type 4 precedes clinical onset of rheumatoid arthritis. Arthritis Rheum. 62, 2633–2639 (2010).
Li, P. et al. Coordination of PAD4 and HDAC2 in the regulation of p53-target gene expression. Oncogene 29, 3153–3162 (2010).
Klareskog, L., Malmstrom, V., Lundberg, K., Padyukov, L. & Alfredsson, L. Smoking, citrullination and genetic variability in the immunopathogenesis of rheumatoid arthritis. Semin. Immunol. 23, 92–98 (2011).
de Pablo, P., Chapple, I. L., Buckley, C. D. & Dietrich, T. Periodontitis in systemic rheumatic diseases. Nat. Rev. Rheumatol. 5, 218–224 (2009).
Detert, J., Pischon, N., Burmester, G. R. & Buttgereit, F. The association between rheumatoid arthritis and periodontal disease. Arthritis Res. Ther. 12, 218 (2010).
Lundberg, K., Wegner, N., Yucel-Lindberg, T. & Venables, P. J. Periodontitis in RA-the citrullinated enolase connection. Nat. Rev. Rheumatol. 6, 727–730 (2010).
Wegner, N. et al. Peptidylarginine deiminase from Porphyromonas gingivalis citrullinates human fibrinogen and α-enolase: implications for autoimmunity in rheumatoid arthritis. Arthritis Rheum. 62, 2662–2672 (2010).
Scher, J. U. et al. Periodontal disease and the oral microbiota in new-onset rheumatoid arthritis. Arthritis Rheum. doi:10.1002/art.34539
Vessey, M. P., Villard-Mackintosh, L. & Yeates, D. Oral contraceptives, cigarette smoking and other factors in relation to arthritis. Contraception 35, 457–464 (1987).
Stolt, P. et al. Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann. Rheum. Dis. 62, 835–841 (2003).
Silman, A. J., Newman, J. & MacGregor, A. J. Cigarette smoking increases the risk of rheumatoid arthritis. Results from a nationwide study of disease-discordant twins. Arthritis Rheum. 39, 732–735 (1996).
Padyukov, L., Silva, C., Stolt, P., Alfredsson, L. & Klareskog, L. A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum. 50, 3085–3092 (2004).
Linn-Rasker, S. P. et al. Smoking is a risk factor for anti-CCP antibodies only in rheumatoid arthritis patients who carry HLA-DRB1 shared epitope alleles. Ann. Rheum. Dis. 65, 366–371 (2006).
Klareskog, L. et al. A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum. 54, 38–46 (2006).
Makrygiannakis, D. et al. Smoking increases peptidylarginine deiminase 2 enzyme expression in human lungs and increases citrullination in BAL cells. Ann. Rheum. Dis. 67, 1488–1492 (2008).
Klareskog, L., Padyukov, L. & Alfredsson, L. Smoking as a trigger for inflammatory rheumatic diseases. Curr. Opin. Rheumatol. 19, 49–54 (2007).
Verpoort, K. N. et al. Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles. Arthritis Rheum. 56, 2913–2918 (2007).
Costenbader, K. H., Chang, S. C., De Vivo, I., Plenge, R. & Karlson, E. W. Genetic polymorphisms in PTPN22, PADI-4, and CTLA-4 and risk for rheumatoid arthritis in two longitudinal cohort studies: evidence of gene-environment interactions with heavy cigarette smoking. Arthritis Res. Ther. 10, R52 (2008).
Kallberg, H. et al. Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis. Am. J. Hum. Genet. 80, 867–875 (2007).
Morgan, A. W. et al. Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. Arthritis Rheum. 60, 2565–2576 (2009).
Kallberg, H. et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann. Rheum. Dis. 70, 508–511 (2011).
Willemze, A. et al. The interaction between HLA shared epitope alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. Arthritis Rheum. 63, 1823–1832 (2011).
Keenan, B. T. et al. Effect of interactions of glutathione S-transferase T1, M1, and P1 and HMOX1 gene promoter polymorphisms with heavy smoking on the risk of rheumatoid arthritis. Arthritis Rheum. 62, 3196–3210 (2010).
Mikuls, T. R. et al. Associations of cigarette smoking with rheumatoid arthritis in African Americans. Arthritis Rheum. 62, 3560–3568 (2010).
Mikuls, T. R. et al. Impact of interactions of cigarette smoking with NAT2 polymorphisms on rheumatoid arthritis risk in African Americans. Arthritis Rheum. 64, 655–664 (2012).
Stolt, P. et al. Silica exposure among male current smokers is associated with a high risk of developing ACPA-positive rheumatoid arthritis. Ann. Rheum. Dis. 69, 1072–1076 (2010).
Colebatch, A. N. & Edwards, C. J. The influence of early life factors on the risk of developing rheumatoid arthritis. Clin. Exp. Immunol. 163, 11–16 (2011).
Mandl, L. A., Costenbader, K. H., Simard, J. F. & Karlson, E. W. Is birthweight associated with risk of rheumatoid arthritis? Data from a large cohort study. Ann. Rheum. Dis. 68, 514–518 (2009).
Karlson, E. W., Mandl, L. A., Hankinson, S. E. & Grodstein, F. Do breast-feeding and other reproductive factors influence future risk of rheumatoid arthritis? Results from the Nurses' Health Study. Arthritis Rheum. 50, 3458–3467 (2004).
Hart, J. E., Laden, F., Puett, R. C., Costenbader, K. H. & Karlson, E. W. Exposure to traffic pollution and increased risk of rheumatoid arthritis. Environ. Health Perspect. 117, 1065–1069 (2009).
Klareskog, L., Catrina, A. I. & Paget, S. Rheumatoid arthritis. Lancet 373, 659–672 (2009).
El-Gabalawy, H. The preclinical stages of RA: lessons from human studies and animal models. Best Clin. Pract. Rheumatol. 23, 49–58 (2009).
Wegner, N. et al. Autoimmunity to specific citrullinated proteins gives the first clues to the etiology of rheumatoid arthritis. Immunol. Rev. 233, 34–54 (2010).
Willemze, A., Trouw, L. A., Toes, R. E. & Huizinga, T. W. The influence of ACPA status and characteristics on the course of RA. Nat. Rev. Rheumatol. 8, 144–152 (2012).
Vossenaar, E. R. et al. The presence of citrullinated proteins is not specific for rheumatoid synovial tissue. Arthritis Rheum. 50, 3485–3494 (2004).
Makrygiannakis, D. et al. Citrullination is an inflammation-dependent process. Ann. Rheum. Dis. 65, 1219–1222 (2006).
Snir, O. et al. Antibodies to several citrullinated antigens are enriched in the joints of rheumatoid arthritis patients. Arthritis Rheum. 62, 44–52 (2010).
Bae, S. et al. α-enolase expressed on the surfaces of monocytes and macrophages induces robust synovial inflammation in rheumatoid arthritis. J. Immunol. 189, 365–372 (2012).
Demoruelle, M. K. et al. Brief Report: Airways abnormalities and rheumatoid arthritis-related autoantibodies in subjects without arthritis: Early injury or initiating site of autoimmunity? Arthritis Rheum. 64, 1756–1761 (2012).
Brown, K. Rheumatoid lung disease. Proc. Am. Thorac. Soc. 4, 443–448 (2007).
Shi, J. et al. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc. Natl Acad. Sci. USA 108, 17372–17377 (2011).
Mydel, P. et al. Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis. J. Immunol. 184, 6882–6890 (2010).
Nielen, M. M. et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50, 380–386 (2004).
Rantapaa-Dahlqvist, S. et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum. 48, 2741–2749 (2003).
Mjaavatten, M. D. et al. The likelihood of persistent arthritis increases with the level of anti-citrullinated peptide antibody and immunoglobulin M rheumatoid factor: a longitudinal study of 376 patients with very early undifferentiated arthritis. Arthritis Res. Ther. 12, R76 (2010).
Vander Cruyssen, B. et al. Prediction models for rheumatoid arthritis during diagnostic investigation: evaluation of combinations of rheumatoid factor, anti-citrullinated protein/peptide antibodies and the human leucocyte antigen-shared epitope. Ann. Rheum. Dis. 66, 364–369 (2007).
Hueber, W. et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann. Rheum. Dis. 66, 712–719 (2007).
Rantapaa-Dahlqvist, S., Boman, K., Tarkowski, A. & Hallmans, G. Up regulation of monocyte chemoattractant protein-1 expression in anti-citrulline antibody and immunoglobulin M rheumatoid factor positive subjects precedes onset of inflammatory response and development of overt rheumatoid arthritis. Ann. Rheum. Dis. 66, 121–123 (2007).
Jorgensen, K. T. et al. Cytokines, autoantibodies and viral antibodies in premorbid and postdiagnostic sera from patients with rheumatoid arthritis: case-control study nested in a cohort of Norwegian blood donors. Ann. Rheum. Dis. 67, 860–866 (2008).
Kokkonen, H. et al. Up-regulation of cytokines and chemokines predates the onset of rheumatoid arthritis. Arthritis Rheum. 62, 383–391 (2010).
El-Gabalawy, H. S. et al. Familial clustering of the serum cytokine profile in the relatives of rheumatoid arthritis patients. Arthritis Rheum. 64, 1720–1729 (2012).
Deane, K. D. et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum. 62, 3161–3172 (2010).
Bevaart, L., Vervoordeldonk, M. J. & Tak, P. P. Evaluation of therapeutic targets in animal models of arthritis: how does it relate to rheumatoid arthritis? Arthritis Rheum. 62, 2192–2205 (2010).
Matsumoto, I. et al. How antibodies to a ubiquitous cytoplasmic enzyme may provoke joint-specific autoimmune disease. Nat. Immunol. 3, 360–365 (2002).
Wipke, B. T., Wang, Z., Nagengast, W., Reichert, D. E. & Allen, P. M. Staging the initiation of autoantibody-induced arthritis: a critical role for immune complexes. J. Immunol. 172, 7694–7702 (2004).
Binstadt, B. A. et al. Particularities of the vasculature can promote the organ specificity of autoimmune attack. Nat. Immunol. 7, 284–292 (2006).
Uysal, H. et al. Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritis. J. Exp. Med. 206, 449–462 (2009).
Uysal, H. et al. Antibodies to citrullinated proteins: molecular interactions and arthritogenicity. Immunol. Rev. 233, 9–33 (2010).
Korb-Pap, A. et al. Early structural changes in cartilage and bone are required for the attachment and invasion of inflamed synovial tissue during destructive inflammatory arthritis. Ann. Rheum. Dis. 71, 1004–1011 (2012).
Kraan, M. C. et al. The development of clinical signs of rheumatoid synovial inflammation is associated with increased synthesis of the chemokine CXCL8 (interleukin-8). Arthritis Res. 3, 65–71 (2001).
Kraan, M. C. et al. Asymptomatic synovitis precedes clinically manifest arthritis. Arthritis Rheum. 41, 1481–1488 (1998).
van de Sande, M. G. et al. Different stages of rheumatoid arthritis: features of the synovium in the preclinical phase. Ann. Rheum. Dis. 70, 772–777 (2011).
van Baarsen, L. G. M. et al. Investigating the cellular composition of lymph nodes in preclinical and early inflammatory arthritis. Arthritis Rheum. 2011, S848 (2011).
Han, Z., Boyle, D. L., Manning, A. M. & Firestein, G. S. AP-1 and NF-κB regulation in rheumatoid arthritis and murine collagen-induced arthritis. Autoimmunity 28, 197–208 (1998).
Fukushima, A., Boyle, D. L., Corr, M. & Firestein, G. S. Kinetic analysis of synovial signalling and gene expression in animal models of arthritis. Ann. Rheum. Dis. 69, 918–923 (2010).
Zhao, X. et al. Circulating immune complexes contain citrullinated fibrinogen in rheumatoid arthritis. Arthritis Res. Ther. 10, R94 (2008).
Willemze, A., Ioan-Facsinay, A. & El-Gabalawy, H. Anti-citrullinated protein antibody response associated with synovial immune deposits in a patient with suspected early rheumatoid arthritis. J. Rheumatol. 35, 2282–2284 (2008).
Mullazehi, M., Mathsson, L., Lampa, J. & Ronnelid, J. High anti-collagen type-II antibody levels and induction of proinflammatory cytokines by anti-collagen antibody-containing immune complexes in vitro characterise a distinct rheumatoid arthritis phenotype associated with acute inflammation at the time of disease onset. Ann. Rheum. Dis. 66, 537–541 (2007).
Mullazehi, M., Mathsson, L., Lampa, J. & Ronnelid, J. Surface-bound anti-type II collagen-containing immune complexes induce production of tumor necrosis factor alpha, interleukin-1beta, and interleukin-8 from peripheral blood monocytes via Fc gamma receptor IIA: a potential pathophysiologic mechanism for humoral anti-type II collagen immunity in arthritis. Arthritis Rheum. 54, 1759–1771 (2006).
Mullazehi, M., Wick, M. C., Klareskog, L., van Vollenhoven, R. & Ronnelid, J. Anti-type II collagen antibodies are associated with early radiographic destruction in rheumatoid arthritis. Arthritis Res. Ther. 14, R100 (2012).
Nandakumar, K. S. et al. Arthritogenic antibodies specific for a major type II collagen triple-helical epitope bind and destabilize cartilage independent of inflammation. Arthritis Rheum. 58, 184–196 (2008).
Snir, O. et al. Multifunctional T cell reactivity to native and glycosylated type-II collagen in rheumatoid arthritis. Arthritis Rheum. 64, 2482–2488 (2012).
Diaz de Stahl, T., Andren, M., Martinsson, P., Verbeek, J. S. & Kleinau, S. Expression of FcgammaRIII is required for development of collagen-induced arthritis. Eur. J. Immunol. 32, 2915–2922 (2002).
Ji, H. et al. Arthritis critically dependent on innate immune system players. Immunity 16, 157–168 (2002).
Kochi, Y. et al. A functional variant in FCRL3, encoding Fc receptor-like 3, is associated with rheumatoid arthritis and several autoimmunities. Nat. Genet. 37, 478–485 (2005).
Cooper, D. L. et al. FcGRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate. PLoS ONE 7, e289018 (2012).
Robinson, J. I. et al. Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. Ann. Rheum. Dis. 69, 1054–1057 (2010).
Okroj, M., Heinegard, D., Holmdahl, R. & Blom, A. M. Rheumatoid arthritis and the complement system. Ann. Med. 39, 517–530 (2007).
Trouw, L. A. et al. Anti-cyclic citrullinated peptide antibodies from rheumatoid arthritis patients activate complement via both the classical and alternative pathways. Arthritis Rheum. 60, 1923–1931 (2009).
Banda, N. K., Takahashi, K., Wood, A. K., Holers, V. M. & Arend, W. P. Pathogenic complement activation in collagen antibody-induced arthritis in mice requires amplification by the alternative pathway. J. Immunol. 179, 4101–4109 (2007).
Rigby, W. F. et al. Increased frequency of complement C4B deficiency in rheumatoid arthritis. Arthritis Rheum. 64, 1338–1344 (2012).
McInnes, I. B. & Schett, G. Cytokines in the pathogenesis of rheumatoid arthritis. Nat. Rev. Immunol. 7, 429–442 (2007).
Firestein, G. S. et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. 37, 644–652 (1994).
Arend, W. P. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev. 13, 323–340 (2002).
Suwannalai, P. et al. Avidity maturation of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum. 64, 1323–1328 (2012).
Lebre, M. C. et al. Rheumatoid arthritis synovium contains two subsets of CD83-DC-LAMP- dendritic cells with distinct cytokine profiles. Am. J. Pathol. 172, 940–950 (2008).
Remmers, E. F. et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N. Engl. J. Med. 357, 977–986 (2007).
Plenge, R. M. et al. TRAF1-C5 as a risk locus for rheumatoid arthritis—a genomewide study. N. Engl. J. Med. 357, 1199–1209 (2007).
Kurreeman, F. A. et al. A candidate gene approach identifies the TRAF1/C5 region as a risk factor for rheumatoid arthritis. PLoS Med. 4, e278 (2007).
Plenge, R. M. et al. Two independent alleles at 6q23 associated with risk of rheumatoid arthritis. Nat. Genet. 39, 1477–1482 (2007).
Matmati, M. et al. A20 (TNFAIP3) deficiency in myeloid cells triggers erosive polyarthritis resembling rheumatoid arthritis. Nat. Genet. 43, 908–912 (2011).
Perkins, E. A. et al. Association of single-nucleotide polymorphisms in CCR6, TAGAP, and TNFAIP3 with rheumatoid arthritis in African Americans. Arthritis Rheum. 64, 1355–1358 (2012).
Kochi, Y. et al. A regulatory variant in CCR6 is associated with rheumatoid arthritis susceptibility. Nat. Genet. 42, 515–519 (2010).
Sui, J. et al. NLRP1 gene polymorphism influences gene transcription and is a risk factor for rheumatoid arthritis in Han chinese. Arthritis Rheum. 64, 647–654 (2012).
Raychaudhuri, S. et al. Common variants at CD40 and other loci confer risk of rheumatoid arthritis. Nat. Genet. 40, 1216–1223 (2008).
Gregersen, P. K. et al. REL, encoding a member of the NF-κB family of transcription factors, is a newly defined risk locus for rheumatoid arthritis. Nat. Genet. 41, 820–823 (2009).
Raychaudhuri, S. et al. Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat. Genet. 41, 1313–1318 (2009).
Stahl, E. A. et al. Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat. Genet. 42, 508–514 (2010).
Chung, Y. L., Lee, M. Y., Wang, A. J. & Yao, L. F. A therapeutic strategy uses histone deacetylase inhibitors to modulate the expression of genes involved in the pathogenesis of rheumatoid arthritis. Mol. Ther. 8, 707–717 (2003).
Nishida, K. et al. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression. Arthritis Rheum. 50, 3365–3376 (2004).
Joosten, L. A., Leoni, F., Meghji, S. & Mascagni, P. Inhibition of HDAC activity by ITF2357 ameliorates joint inflammation and prevents cartilage and bone destruction in experimental arthritis. Mol. Med. 17, 391–396 (2011).
Grabiec, A. M., Korchynskyi, O., Tak, P. P. & Reedquist, K. A. Histone deacetylase inhibitors suppress rheumatoid arthritis fibroblast-like synoviocyte and macrophage IL-6 production by accelerating mRNA decay. Ann. Rheum. Dis. 71, 424–431 (2012).
Richardson, B. et al. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum. 33, 1665–1673 (1990).
Liu, C. C. et al. Global DNA methylation, DNMT1, and MBD2 in patients with rheumatoid arthritis. Immunol. Lett. 135, 96–99 (2011).
Neidhart, M. et al. Retrotransposable L1 elements expressed in rheumatoid arthritis synovial tissue: association with genomic DNA hypomethylation and influence on gene expression. Arthritis Rheum. 43, 2634–2647 (2000).
Ali, M. et al. Overexpression of transcripts containing LINE-1 in the synovia of patients with rheumatoid arthritis. Ann. Rheum. Dis. 62, 663–666 (2003).
Karouzakis, E., Gay, R. E., Michel, B. A., Gay, S. & Neidhart, M. DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 60, 3613–3622 (2009).
Karouzakis, E. et al. DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts. Genes Immun. 12, 643–652 (2011).
Nakano, K., Whitaker, J. W., Boyle, D. L., Wang, W. & Firestein, G. S. DNA methylome signature in rheumatoid arthritis. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-201526.
Karouzakis, E., Gay, R. E., Gay, S. & Neidhart, M. Increased recycling of polyamines is associated with global DNA hypomethylation in rheumatoid arthritis synovial fibroblasts. Arthritis Rheum. 64, 1809–1817 (2012).
Nakasa, T. et al. Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum. 58, 1284–1292 (2008).
Nakamachi, Y. et al. MicroRNA-124a is a key regulator of proliferation and monocyte chemoattractant protein 1 secretion in fibroblast-like synoviocytes from patients with rheumatoid arthritis. Arthritis Rheum. 60, 1294–1304 (2009).
Niederer, F. et al. Down-regulation of microRNA-34* in rheumatoid arthritis synovial fibroblasts promotes apoptosis resistance. Arthritis Rheum. 64, 1771–1779 (2012).
Author information
Authors and Affiliations
Contributions
Both authors made substantial contributions to researching data for the article, discussions of content, writing the article and review and/or editing of the article before submission.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Arend, W., Firestein, G. Pre-rheumatoid arthritis: predisposition and transition to clinical synovitis. Nat Rev Rheumatol 8, 573–586 (2012). https://doi.org/10.1038/nrrheum.2012.134
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.134
This article is cited by
-
Advancement in nanotechnology for treatment of rheumatoid arthritis: scope and potential applications
Naunyn-Schmiedeberg's Archives of Pharmacology (2023)
-
Identification of potential autoantigens in anti-CCP-positive and anti-CCP-negative rheumatoid arthritis using citrulline-specific protein arrays
Scientific Reports (2021)
-
Immune-mediated inflammatory disease therapeutics: past, present and future
Nature Reviews Immunology (2021)
-
Bioinformatics-based study to identify immune infiltration and inflammatory-related hub genes as biomarkers for the treatment of rheumatoid arthritis
Immunogenetics (2021)
-
Inhibition of glycolysis ameliorate arthritis in adjuvant arthritis rats by inhibiting synoviocyte activation through AMPK/NF-кB pathway
Inflammation Research (2020)